

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

***Listing of Claims***

1. **(Currently Amended)** A combination comprising roscovitine, or an enantiomer thereof, a CDK inhibitor and 1-(2-C-cyano-2-dioxy- $\beta$ -D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, wherein the metabolite is 1-(2-C-Cyano-2-deoxy- $\beta$ -D-arabino-pentafuranosyl)-cytosine.

2-5. **(Canceled)**

6. **(Previously Presented)** A pharmaceutical composition comprising a combination according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.

7. **(Canceled)**

8. **(Currently Amended)** A pharmaceutical product comprising roscovitine, or an enantiomer thereof, a CDK inhibitor and 1-(2-C-cyano-2-dioxy- $\beta$ -D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, wherein the metabolite is 1-(2-C-Cyano-2-deoxy- $\beta$ -D-arabino-pentafuranosyl)-cytosine, as a combined preparation for simultaneous, sequential or separate use in therapy.

9-11. **(Canceled)**

12. **(Previously Presented)** A pharmaceutical product according to claim 8 in the form of a pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent or excipient.

13. **(Currently Amended)** A pharmaceutical product according to claim 8 ~~claims 8~~ for use in the treatment of a proliferative disorder, wherein the proliferative disorder is selected from lung cancer, prostate cancer, bladder cancer, head and neck cancer, colon cancer, sarcoma and lymphoma.

14-16. (Canceled)

17. **(Currently Amended)** A method of treating a proliferative disorder, wherein the proliferative disorder is selected from lung cancer, prostate cancer, bladder cancer, head and neck cancer, colon cancer, sarcoma and lymphoma, said method comprising administering to a subject, simultaneously, sequentially or separately, 1-(2-C-cyano-2-dioxy- $\beta$ -D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, wherein the metabolite is 1-(2-C-Cyano-2-deoxy- $\beta$ -D-arabino-pentafuranosyl)-cytosine, and roscovitine ~~a CDK inhibitor~~.

18. **(Currently Amended)** A method according to claim 17 which comprises administering roscovitine ~~said CDK inhibitor~~ to a subject prior to sequentially or separately administering 1-(2-C-cyano-2-dioxy- $\beta$ -D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, to said subject.

19. **(Currently Amended)** A method according to claim 17 which comprises administering 1-(2-C-cyano-2-dioxy- $\beta$ -D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, to a subject prior to sequentially or separately administering roscovitine ~~a CDK inhibitor~~ to said subject.

20-22. (Canceled)

23. **(Currently Amended)** A method according to claim 17 wherein the roscovitine ~~CDK inhibitor~~ and 1-(2-C-cyano-2-dioxy- $\beta$ -D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, are each administered in a therapeutically effective amount with respect to the individual components.

24. **(Currently Amended)** A method according to claims 17 wherein the roscovitine ~~CDK inhibitor~~ and 1-(2-C-cyano-2-dioxy- $\beta$ -D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, are each administered in a subtherapeutic amount with respect to the individual components.

25-31. (Canceled)